Safety of Outpatient Parenteral Antimicrobial Therapy for Endocarditis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Sir—Andrews and von Reyn [1] raise concerns about the use of outpatient parenteral antimicrobial therapy (OPAT) for endocarditis and provide reasonable recommendations for dealing with them. Their experience with 2 deaths is a lesson for us all. Decisions about OPAT require a thorough knowledge of serious infections and iv antibiotic therapy. Patient selection for OPAT requires a review of the factors the authors mention but also needs an assessment of the home situation, with which physicians are often not familiar [2]. The need for close monitoring and observation of outpatients receiving iv antibiotics may not be appreciated by either hospital physicians, whose purview and responsibilities may be limited to the hospital, or by the ambulatory care physician, who may have little knowledge or experience with what have traditionally been hospital infections. Although Andrews and von Reyn [1] point out the increased risks of complications of endocarditis during the first 2 weeks of therapy, it is important to note also that the risks of iv antimicrobial therapy increase with time, even if the infection responds well clinically. The likelihood of vestibular toxicity or nephrotoxicity with use of gentamicin and leukopenia with use of β-lactams or vancomycin clearly increases after 2 weeks of therapy, which is just when the risk of complications of endocarditis wanes [3, 4]. Physicians must remain vigilant throughout the course of OPAT and perform regular examinations and laboratory monitoring. The OPAT Outcomes Registry has been designed to answer some of the questions that Andrews and von Reyn [1] pose about safety and outcomes with OPAT [5–7]. Of the 7800 recorded patients who received OPAT since 1996 at 24 centers around the United States, 198 had a diagnosis of bacterial endocarditis; 44 of these cases were due to Staphylococcus aureus. OPAT was ended early for 30 patients (15%) for reasons that included death, for 2 patients; 1 death was related to placement of a central line in the hospital, and 1 was due to a stroke that occurred after 14 days of OPAT. Twenty-six patients were hospitalized. The reasons included the following: surgery, for 6 patients (1 of whom required urgent surgery); conditions unrelated to OPAT, for 16 patients; and complications of OPAT, for 4 patients. Rates of hospitalization are often higher for endocarditis than for other infections [8–10]. Courses of antibiotic therapy were changed for 15 patients (7.5%) due to adverse antibiotic effects, which included fever (5 patients), renal toxicity (4), and leukopenia (1). The careful review by Andrews and von Reyn [1] should be a valuable guide for physicians while further information is being collected by the OPAT Outcomes Registry regarding the benefits, risks, and potential pitfalls of OPAT for various disease states. It is critical that physicians take an active rather than passive role in managing OPAT in order to assure that the quality of care is as good as it is in the hospital.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Outpatient parenteral antibiotic therapy (OPAT) is efficacious, safe, and cost-effective for a variety of infections, [323][324][325] including IE that requires prolonged parenteral therapy in hospitalized patients who otherwise no longer require inpatient care but do require continued parenteral antimicrobial therapy.”
Citations
Cites
Andrews, M., & von Reyn, C. F. (2001) · Clinical Infectious Diseases · doi:10.1086/321814 · Cited by 129 · cited 6×
“Sir—Andrews and von Reyn [1] raise concerns about the use of outpatient parenteral antimicrobial therapy (OPAT) for endocarditis and provide reasonable recommendations for dealing with them.”
BackgroundMethodResultInfluentialOlaison, L., Belin, L., Hogevik, H., & Alestig, K. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.6.607 · Cited by 81
Tablan, O. C., Reyes, M. P., Rintelmann, W. F., et al. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/149.2.257 · Cited by 69
Tice, A. (2001) · Chemotherapy · doi:10.1159/000048563 · Cited by 45
Self-citationCampion, E. W. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712183372511 · Cited by 40
Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents
Williams, D. N. (1995) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(94)00046-w · Cited by 39
OUTPATIENT INTRAVENOUS ANTIBIOTIC THERAPY FOR ENDOCARDITIS
Rehm, S. J. (1998) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70026-x · Cited by 37
The importance of teamwork for outpatient parenteral antibiotic therapy
Tice, A. D. (1995) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(94)00052-v · Cited by 19
Self-citation
Research works printed but not linked: 2
- 2000, 10, 45
- 2000, American journal of infection control, 1, 42
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Metadata
- Authors
- Tice, A. D.
- Corresponding author
- Tice, A. D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-02-01
- Volume
- 34
- Issue
- 3
- Pages
- 419-420
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2124890011
- Cited by
- 10
- References
- 8
- Citations by year
- 2023: 1 · 2017: 1 · 2015: 2 · 2013: 1 · 2012: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- outpatient parenteral antimicrobial therapy, bacterial endocarditis, patient selection, adverse drug reactions, gentamicin nephrotoxicity, Staphylococcus aureus endocarditis, hospitalization, central line complications, stroke, patient monitoring, outpatient care
- MeSH terms
- Anti-Infective Agents, Endocarditis, Bacterial, Humans, Infusions, Parenteral, Outpatients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Outpatient Parenteral Antimicrobial Therapy for Endocarditis. https://app.cochat.ai/papers/10.1086/324369
- The paper
- Tice, A. D. (2002). Safety of Outpatient Parenteral Antimicrobial Therapy for Endocarditis. Clinical Infectious Diseases. https://doi.org/10.1086/324369
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.